NDAORALFOR SOLUTION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
SDAMLO (amlodipine) by BrilliantStrings Therapeutics is (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. First approved in 2025.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SDAMLO (amlodipine) is an oral calcium channel blocker approved in July 2025 for hypertension and angina. It works by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, reducing peripheral vascular resistance and blood pressure while relieving anginal chest pain. The drug acts as a peripheral arterial vasodilator with selective effects on vascular tissue over cardiac tissue.
Growth
Early-stage launch phase with moderate competitive pressure (30% score) suggests growing field team and commercial infrastructure investment.
Mechanism of Action
(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…
Indications
Worked on SDAMLO at BrilliantStrings Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.